Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

by · The Markets Daily

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $6.75.

A number of equities analysts have recently weighed in on CMPX shares. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. D. Boral Capital began coverage on Compass Therapeutics in a research report on Monday. They set a “buy” rating and a $32.00 price objective on the stock. Leerink Partnrs cut shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, November 11th. Finally, Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th.

Get Our Latest Stock Analysis on CMPX

Compass Therapeutics Price Performance

Shares of CMPX opened at $1.38 on Monday. The company’s 50-day moving average is $1.65 and its 200-day moving average is $1.41. The firm has a market capitalization of $189.87 million, a PE ratio of -3.73 and a beta of 0.89. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34.

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Analysts predict that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC increased its holdings in Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after buying an additional 5,515 shares during the period. Rhumbline Advisers boosted its position in shares of Compass Therapeutics by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company’s stock worth $132,000 after acquiring an additional 12,315 shares in the last quarter. Rovin Capital UT ADV bought a new position in Compass Therapeutics in the third quarter valued at approximately $25,000. Intech Investment Management LLC acquired a new position in Compass Therapeutics during the third quarter valued at approximately $30,000. Finally, Geode Capital Management LLC lifted its stake in Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

(Get Free Report

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

See Also